Partnering
Contact
Contact Information
Join Us
EN
CN
About Us
CMS Overview
Leadership
Milestones
Social Responsibility
Innovation
R&D Overview
Pipeline
Business
Business Overview
Cardio-cerebrovascular and Gastroenterology
Skin Health Business
Ophthalmology
Southeast Asia & the Middle East Business
News
Company News
Partner News
Video News
Investors
Stock Infomation
Financial Highlights
Information Disclosure
Corporate Governance
Investor Communication
Home
About Us
CMS Overview
Leadership
Milestones
Social Responsibility
Innovation
R&D Overview
Pipeline
Business
Business Overview
Cardio-cerebrovascular and Gastroenterology
Dermatology and Medical Aesthetics
Ophthalmology
News
Company News
Partner News
Investors
Investors
Stock Infomation
Financial Highlights
Information Disclosure
Corporate Governance
Partnering
Contact
Contact Information
Join Us
EN
CN
2022-07-08
Won the “Best Hong Kong Stock-Connect Company” from Golden Hong Kong Listed Companies
Honored with three awards including “2019 Top 10 Listed Companies with the Highest Investment Value in China Pharmaceutical Industry”, “Top 100 Innovative Pharmaceutical Enterprises in China” and “Benchmarking Enterprises in Pharmaceutical Industry at the 70th Anniversary of PRC Founding” at the China Healthcare Summit of Entrepreneurs, Scientists and Investors
Tibet Kangzhe was awarded the “Top 20 Private Enterprises of Tibet Autonomous Region”
Obtained the clinical trial notice of Diazepam Nasal Spray from China NMPA
Acquired product rights of seven innovative products including Cyclosporine Eye Drops 0.09%, Tildrakizumab Solution for Injection and Paclitaxel Injection Concentrate for Suspension in Mainland China and/or other countries or regions
Acquired product rights of 11 generics (including a complex generic) in Mainland China and/or other countries or regions
